Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

39.47 -0.02 (-0.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,328,881
Open 39.53
Bid (Size) 35.00 (1)
Ask (Size) 41.23 (1)
Prev. Close 39.49
Today's Range 38.90 - 39.87
52wk Range 25.04 - 43.20
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter. 
Via Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
+21.07%
+21.07%
1 Month
-5.42%
-5.42%
3 Month
+25.94%
+25.94%
6 Month
+28.78%
+28.78%
1 Year
+11.40%
+11.40%

More News

Read More
Recap: Ionis Pharmaceuticals Q1 Earnings
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Expert Ratings For Ionis Pharmaceuticals
Via Benzinga
Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks
Via Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Via Benzinga
How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
Via Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Via Investor's Business Daily
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Via Benzinga
Pfizer Backs Out Of Heart-Disease Deal, Leaving Ionis Stock To Crumble
Via Investor's Business Daily
Why Are Ionis Pharmaceuticals Shares Tanking Today?
Via Benzinga
Why Cramer Likes Ferguson And Stanley Black & Decker
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For March 11, 2022: Tesla, DTE Energy, Amazon And More
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 25, 2022: GameStop, Tesla, AMD And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 23, 2022: Palantir, GameStop, Tesla, And More
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 22, 2022: Tesla, GameStop, Lexicon And More
Via Benzinga
Bear Market Bets In Biotech
Via Talk Markets
BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?
Via Benzinga
Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot?
Via Investor's Business Daily
Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.